Clinical Trial Search

Primary: Effectiveness of Oxymetazoline in the Treatment of Rhinitis With Persistent Nasal Obstruction — 1.38; 1.67 units on a scale

Primary: Systolic Blood Pressure at Screening/Visit 1, Visit 2, and Visit 3 — 110.98; 110.63; 110.00 millimeters of mercury (mmHg) — p=>0.05

Primary: Runny Nose as Measured by the Visual Analog Scale (VAS) at Baseline — 6.07 score on a scale

Primary: Change in Visual Analogue Scale for Major Nasal Symptoms — 3.66; 4.29; 4.49; 5.6 score on a scale

Primary: Cmax (the Maximum Observed Plasma Concentration) — 1630.223; 1729.393; 1617.810 ng/mL

Primary: Allergic Rhinitis Symptom Score Including Rhinorrhea, Nasal Obstruction, Sneezing, Itchy Nose and Itchy Eyes at Week 4 — 2.82; 2.8; 1.19; 1.21 Unit Score

Primary: Eosinophilic Cationic Protein (ECP) Levels

Primary: Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Week 2 — -1.96; -1.94; -1.87 Score on a Scale — p=0.661

Primary: The Change of the Rhinasthma Global Summary Score From Baseline to Endpoint After 28 Days of Treatment. — 25.3; 26.7; -10.3; 0.4 units on a scale — p=0.001

Primary: Change From Diluent Challenge Contralateral Secretion Weight at Antigen Challenge — 6; 19.6 milligrams

Primary: Difference in German Cockroach-Specific Serum IgE Over Time — 2.16; 1.12 Ratio — p=<0.0001

Primary: Change From Baseline in the Total Nasal Symptom Score at 2 Weeks — -3.9850; -1.9081 score on a scale — p=<0.0001

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Averaged Over the 6-week Treatment Period in Patients With Perennial Allergic Rhinitis — -0.37; -0.44 Score on…

Primary: Change From Baseline in D. Farinae HDM-specific IgG4 Antibodies in Serum at 12 Weeks (Part 2) — 0.392; 0.166 Fold Change — p=0.003

Primary: Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of Treatment — 9.63; 9.55; -3.76; -2.87 units on a scale — p=<.001